Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 2/20 | 0.43 |
| ▸ | CCNH | P51946 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 11/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665634 | 0.89 | HTR6 (0.50) | EGFR | |
| SCHEMBL18074114 | 0.88 | EGFR (0.43) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL18074097 | 0.76 | CDK7 (0.56) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL18074117 | 0.75 | TSHR (0.44) | CDK7CCNHEGFRTP53 | |
| SCHEMBL18074116 | 0.69 | CDK9 (0.48) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL19040086 | 0.69 | CDK7 (0.51) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL19040122 | 0.65 | CDK7 (0.43) | CDK7CCNHCCNT1CDK9MNAT1 | |
| SCHEMBL16665592 | 0.65 | EGFR (0.51) | CDK7CCNHCCNT1CDK9EGFR | |
| SCHEMBL29613438 | 0.65 | EGFR (0.51) | CDK7CCNHCCNT1CDK9EGFR | |
| SCHEMBL18069821 | 0.64 | CDK7 (0.57) | CDK7CCNHCCNT1CDK9MNAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | CDK7 1/4885CCNH 32/4885CCNT1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.